

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC. NO.
LR/G-3298
APPLICATION NO.
Not Yet Known
APPLICANT
KRISCH ET AL.
FILING DATE
Herewith

10/539501

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,935,429	6/19/90	Dackis et al.			
	AB	5,430,031	7/4/95	Brambilla et al.			
	AC	5,441,961	8/15/95	Cohen et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	01/41763	6/14/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Milivojevic et al., "A Novel Ergoline Derivative LEK-8829 Attenuates Cocaine-Induced Reinstatement of Cocaine-Seeking Behavior", Behavioural Pharmacology, Vol. 14, No. Suppl. 1, p. S55 (2003).
AS	Glavan et al., "Modulation of Neuroleptic Activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimalate (LEK-8829) by D1 Intrinsic Activity in Hemi-Parkinsonian Rats", Molecular Pharmacology, Vol. 61, No. 2, pp. 360-368 (2002).
AT	Zivin et al., "Antiparkinsonian Potential of Interaction of LEK-8829 with Bromocriptine", European Journal of Pharmacology, Vol. 349, No. 2-3, pp. 151-157 (1998).

EXAMINER

/Sahar Javanmard/

DATE CONSIDERED 04/28/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./